After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path
JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according…
Novo Nordisk’s Wegovy Gets A Logistics Boost – EU Eases Shipping Rules
Novo said the European Medicines Agency approved transporting its blockbuster Wegovy injection at up to 30°C for up…
Novo Nordisk Claims Lead Over Lilly’s Newly Approved Pill
The study also showed discontinuation rates due to gastrointestinal events were roughly 14 times higher with orforglipron. Results…
Novo Nordisk Cuts Wegovy Costs With Subscription Model For US Patients
Novo said patients can save up to $600 per year on Wegovy pills and up to $1,200 per…
Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal
The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and…